Several clinical studies demonstrated that diabetic patients treated with metformin were less likely to develop vascular complications, independent of glycemic control. It was also demonstrated that the large variety of metformin's vascular actions can be seen in nondiabetic conditions. Metformin has an interesting potential to treat vascular dysfunction and tumor angiogenesis in conditions beyond diabetes. Since metformin's use in cancer as a single antiangiogenic agent appears to be a therapeutic disappointment, the use of the drug as part of combination anticancer modality represents a therapeutic challenge. The normalization of vascular dysfunction as a new therapeutic strategy may provide better delivery of conventional anticancer agents to the tumor and disrupted tumor environment. In this review, we will outline the available information from the literature regarding metformin and tumor angiogenesis and suggest eventual experimental and clinical approaches.

Keywords:
Metformin, Angiogenesis, Cancer
1.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ  1998;317:703-713.
2.
Chong CR, Chabner BA: Mysterious metformin. Oncologist 2009;14:1178-1181.
3.
Pollak M: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010;3:1060-1065.
4.
Dowling RJ, Niraula S, Stambolic V, et al: Metformin in cancer: translational challenges. J Mol Endocrinol 2012;48:31-43.
5.
Wiernsperger NF: Review: 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis 2007;7:204-210.
6.
Schafer G: Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes. Biochem Pharmacol 1976;25:2015-2024.
7.
Wiernsperger NF: Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2000;2:259-272.
8.
Kraemer de Aguiar LG, Laflor CM, Bahia L, et al: Metformin improves skin capillary reactivity in normoglycaemia subject with the metabolic syndrome. Diabet Med 2007;24:272-279.
9.
Wiernsperger N, Nivoit P, de Augiar LG, et al: Microcirculation and the metabolic syndrome. Microcirculation 2007;14:403-438.
10.
Folkman J: Tumor angiogenesis: therapeutic implication. N Engl J Med 1971;285:1182-1186.
11.
Nagy JA, Chang SH, Shih SC, et al: Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010;36:321-331.
12.
Bergers G, Song S: The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7:452-464.
13.
Nolan DJ, Ciarrocchi A, Mellick AS, et al: Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007;21:1546-1558.
14.
Hellström M, Gerhardt H, Kalén M, et al: Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153:543-553.
15.
Armulik A, Abramsson A, Betsholtz C, et al: Endothelial/pericyte interactions. Circ Res 2005;97:512-523.
16.
Nagy JA, Chang HS, Dvorak AM: Why are tumor blood vessels abnormal and why is it important to know? Br J Cancer 2009;100:865-869.
17.
Leenders WP, Küsters B, de Waal RM: Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002;9:83-87.
18.
Jain RK: Normalization of tumor vasculature: an emerging concept on antiangiogenic therapy. Science 2005;307:58-62.
19.
Sandoo A, Kitas GD, Carmichael AR: Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Research 2014;34:1147-1152.
20.
Lerman A, Zeiher A: Endothelial function: cardiac events. Circulation 2005;111:363-368.
21.
Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
22.
Varadharaj S, Steinhour E, Hunter MG, et al: Vitamin C-induced activation of phospholipase D in lung microvascular endothelial cells: regulation by MAP kinases. Cell Signal 2006;18:1396-1407.
23.
Eringa EC, Serne EH, Meijer RI, et al: Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 2013;14:39-48.
24.
Ribatti D, Vacca A, Dammaco F: The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999;1:293-302.
25.
Pournaras C, Strommer K, Tsacopoulos M, et al: Experimental branch vein occlusion in miniature pigs: effects of metformin on the evolution of the ischemic microangiopathy. Diabetes Metab 1988;14:580-586.
26.
Bergers G, Benjamin LE: Angiogenesis: tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
27.
Palomba S, Falbo A, Zullo F, et al: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50.
28.
Tosca L, Solnais P, Ferré P, et al: Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 2006;75:342-351.
29.
Viollet B, Guigas B, Garcia N, et al: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-270.
30.
Ersoy C, Kiyici S, Budak F, et al: The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008;81:56-60.
31.
Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
32.
Cline EI, Bicciato S, DiBello C, et al: Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res 2002;15;62:7143-7148.
33.
Xavier DO, Amaral LS, Gomes MA, et al: Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 2010;64:220-225.
34.
Dallaglio K, Bruno A, Cantelmo A, et al: Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis 2014;35:1055-1066.
35.
Rivera LB, Bergers G: Targeting vascular sprouts - manipulating metabolism could control angiogenesis. Science 2014;344:1449-1450.
36.
Baeriswyl V, Christofori G: The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009;19:329-337.
37.
Weis SM, Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-1370.
38.
Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 2001;473:298-307.
39.
Tadakawa M, Takeda T, Li B, et al: The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. Mol Cell Endocrinol 2015;399:1-8.
40.
Karar J, Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51.
41.
Skinner HD, Zheng JZ, Fang J, et al: Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004;279:45643-45651.
42.
Laughner E, Taghavi P, Chiles K, et al: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
43.
Lu-Emerson C, Duda DG, Emblem KE, et al: Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015;33:1197-1213.
44.
Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to angiogenic therapy. Natl Rev Clin Oncol 2009;6:327-338.
45.
Willet CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
46.
Nathan P, Zweifel M, Padhani AR, et al: Phase 1 trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 2012;18:3428-3439.
47.
Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563.
48.
Esfahanian N, Shakiba Y, Nikbin B: Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol Med Rep 2012;5:1068-1074.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.